Your browser does not support JavaScript
KD025-209 Study

KD025-209 Study


KD025-209 Study

What is the purpose of the KD025-209 study?

The main purpose of the KD025-209 study is to see whether a new study drug, belumosudil, is safe and effective for helping people with scleroderma. Belumosudil is not currently approved by the U.S. Food and Drug Administration (FDA) or any other regulatory body as a scleroderma therapy.

The Study Drug

Who can participate in the KD025-209 study?

You may qualify for the KD025-209 study if you meet the following basic requirements:
  • You are at least 18 years old
  • You have been diagnosed with scleroderma within the last 5 years
  • If taking immunosuppressant medications, you have been taking a stable dose for at least 3 months before starting the study
Important: Other requirements will apply.

What can participants expect?

Participants can expect the following during the 60-week study:
  • Visit the study clinic to find out if you qualify
  • Take the study drug or placebo (no active drug ingredients) for 52 weeks and visit the study clinic monthly. All participants will receive the study drug at some point during the 52-week period
  • Check in with the study doctor after you stop taking the study drug
For more information about what to expect during the study, visit the KD025-209 webpage or use the study clinic locator to find a doctor near you.

Study Clinic Locator

Copyright © 2022   |  KD025-209 Study  |   All Rights Reserved   |  Privacy  HIPPA  |  Terms & Conditions